The current experiments showed that TIC, when administered at a dose that inhibits platelet aggregation to the same degree as CLO, protects against atherosclerosis more robustly than CLO (Fig 2A & 2B) likely through its unique ability to induce PON1 (Fig 5). Here, PON1 is linked to atherosclerosis.